Supernus resumes coverage with overweight rating; target price $47
SUPN•Piper Sandler resumed coverage of Supernus Pharmaceuticals with an overweight rating and a $47 target price.
Related News
Revolve Group, Inc.: Piper Sandler cuts target price to $26 from $30
RVLV•
DigitalOcean Holdings: Baird cuts target price to $130 from $165
DOCN•
Upstart Holdings: Piper Sandler cuts target price to $35 from $51
UPST•
Canaccord Genuity raises Ceribell target price to $33 from $26
CBLL•
B. Riley cuts Booking Holdings target price to $265 from $274
BKNG•